162 related articles for article (PubMed ID: 9212914)
1. Antisense-protein kinase A: a single-gene-based therapeutic approach.
Cho-Chung YS; Nesterova M; Kondrashin A; Noguchi K; Srivastava R; Pepe S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):217-23. PubMed ID: 9212914
[No Abstract] [Full Text] [Related]
2. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C as a target for cancer therapy.
Glazer RI
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
[No Abstract] [Full Text] [Related]
4. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
5. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth.
Nesterova M; Cho-Chung YS
Nat Med; 1995 Jun; 1(6):528-33. PubMed ID: 7585118
[TBL] [Abstract][Full Text] [Related]
6. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
[TBL] [Abstract][Full Text] [Related]
7. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
10. cAMP-dependent protein kinase: role in normal and malignant growth.
Cho-Chung YS; Pepe S; Clair T; Budillon A; Nesterova M
Crit Rev Oncol Hematol; 1995 Nov; 21(1-3):33-61. PubMed ID: 8822496
[No Abstract] [Full Text] [Related]
11. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
Yokozaki H; Budillon A; Tortora G; Meissner S; Beaucage SL; Miki K; Cho-Chung YS
Cancer Res; 1993 Feb; 53(4):868-72. PubMed ID: 8428367
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
13. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
15. Overview of novel anticancer drug targets.
Buolamwini JK; Assefa H
Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193
[No Abstract] [Full Text] [Related]
16. Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray.
Cho-Chung YS
Biochim Biophys Acta; 2004 Mar; 1697(1-2):71-9. PubMed ID: 15023351
[TBL] [Abstract][Full Text] [Related]
17. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
Nesterova M; Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide.
Ackermann K; Fauss J; Pyerin W
Cancer Res; 1994 Sep; 54(18):4940-6. PubMed ID: 8069860
[TBL] [Abstract][Full Text] [Related]
19. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis of drug-resistant human ovarian carcinoma cell line COC1/DDP induced by survivin antisense oligonucleotides.
Zheng F; Ruan F; Xie XK; Liu SY
Chin Med J (Engl); 2006 Sep; 119(18):1572-5. PubMed ID: 16996013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
